Anti-PDGF-B monoclonal antibody reduces liver fibrosis development

Hepatology Research

Volumn 40, Issue 11, 2010, Pages 1128-1141

  Ogawa, Shinji ^a,b,c   Ochi, Takashi ^b   Shimada, Hideaki ^a,b   Inagaki, Kazuyuki ^b   Fujita, Isami ^b   Nii, Aisuke ^c   Moffat, Mark A ^d   Katragadda, Madan ^c   Violand, Bernard N ^c   Arch, Robert H ^a,c   Masferrer, Jaime L ^a  

^a Inflammation Research Unit   (United States)

^b Discovery Biology   (Japan)

^c PFIZER INC   (United States)

^d Pfizer Global Research and Development ^*  (United States)

Author keywords

Bile duct ligation; Concanavalin A; Hepatitis; Liver fibrosis; Monoclonal antibody; PDGF

Indexed keywords

ABYD 3263; ALANINE AMINOTRANSFERASE; CONCANAVALIN A; HYDROXYPROLINE; MONOCLONAL ANTIBODY; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR BB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; BILE DUCT LIGATION; CELL ASSAY; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; DRUG HALF LIFE; IN VITRO STUDY; LIVER FIBROSIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; STELLATE CELL;

EID: 77958607056     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2010.00718.x     Document Type: Article

References (34)

1. Henderson NC, Iredale JP. Liver fibrosis: cellular mechanisms of progression and resolution. Clin Sci (Lond) 2007; 112: 265-80.
2. Fredriksson L, Li H, Eriksson U. The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev 2004; 15: 197-204.
3. Pinzani M. PDGF and signal transduction in hepatic stellate cells. Front Biosci 2002; 7: d1720.
4. Ikura Y, Morimoto H, Ogami M, Jomura H, Ikeoka N, Sakurai M. Expression of platelet-derived growth factor and its receptor in livers of patients with chronic liver disease. J Gastroenterol 1997; 32: 496-501.
5. Pinzani M, Milani S, Herbst H et-al. Expression of platelet-derived growth factor and its receptors in normal human liver and during active hepatic fibrogenesis. Am J Pathol 1996; 148: 785-800.
6. Kinnman N, Hultcrantz R, Barbu V et-al. PDGF-mediated chemoattraction of hepatic stellate cells by bile duct segments in cholestatic liver injury. Lab Invest 2000; 80: 697-707.
7. Grappone C, Pinzani M, Parola M et-al. Expression of platelet-derived growth factor in newly formed cholangiocytes during experimental biliary fibrosis in rats. J Hepatol 1999; 31: 100-9.
8. Bonner JC. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev 2004; 15: 255-73.
9. Kinnman N, Goria O, Wendum D et-al. Hepatic stellate cell proliferation is an early platelet-derived growth factor-mediated cellular event in rat cholestatic liver injury. Lab Invest 2001; 81: 1709-16.
10. Kinnman N, Francoz C, Barbu V et-al. The myofibroblastic conversion of peribiliary fibrogenic cells distinct from hepatic stellate cells is stimulated by platelet-derived growth factor during liver fibrogenesis. Lab Invest 2003; 83: 163-73.
11. Borkham KE, Stoll D, Gressner AM, Weiskirchen R. Antisense strategy against PDGF B-chain proves effective in preventing experimental liver fibrogenesis. Biochem Biophy Res Commun 2004; 321: 413-23.
12. Borkham KE, Herrmann J, Stoll D, Treptau J, Gressner AM, Weiskirchen R. Dominant-negative soluble PDGF-beta receptor inhibits hepatic stellate cell activation and attenuates liver fibrosis. Lab Invest 2004; 84: 766-77.
13. Neef M, Ledermann M, Saegesser H et-al. Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term. J Hepatol 2006; 44: 167-75.
14. Yoshiji H, Noguchi R, Kuriyama S et-al. Imatinib mesylate STI-571 attenuates liver fibrosis development in rats. Am J Physiol Gastrointest Liver Physiol 2005; 288: G907-13.
15. Czochra P, Klopcic B, Meyer E et-al. Liver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice. J Hepatol 2006; 45: 419-28.
16. Druker BJ, Tamura S, Buchdunger E et-al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561-6.
17. Buchdunger E, Cioffi CL, Law N et-al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295: 139-45.
18. Krebs B, Rauchenberger R, Reiffert S et-al. High-throughput generation and engineering of recombinant human antibodies. J Immunol Methods 2001; 254: 67-84.
19. Waltenberger J, Claesson WL, Siegbahn A, Shibuya M, Heldin CH. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 1994; 269: 26988-95.
20. Roberts WG, Whalen PM, Soderstrom E et-al. Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673, 451. Cancer Res 2005; 65: 957-66.
21. Murakami K, Abe T, Miyazawa M et-al. Establishment of a new human cell line, LI90, exhibiting characteristics of hepatic Ito fat-storing cells. Lab Invest 1995; 72: 731-9.
22. Kountouras J, Billing BH, Scheuer PJ. Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat. Br J Exp Pathol 1984; 65: 305-11.
23. Reddy GK, Enwemeka CS. A simplified method for the analysis of hydroxyproline in biological tissues. Clin Biochem 1996; 29: 225-9.
24. Lee SS, Girod C, Braillon A, Hadengue A, Lebrec D. Hemodynamic characterization of chronic bile duct-ligated rats: effect of pentobarbital sodium. Am J Physiol 1986; 251: G176-80.
25. Borkham KE, Van Roeyen CRC, Ostendorf T, Floege J, Gressner AM, Weiskirchen R. Pro-fibrogenic potential of PDGF-D in liver fibrosis. J Hepatol 2007; 46: 1064-74.
26. Tsuneyama K, Kono N, Yamashiro M et-al. Aberrant expression of stem cell factor on biliary epithelial cells and peribiliary infiltration of c-kit-expressing mast cells in hepatolithiasis and primary sclerosing cholangitis: a possible contribution to bile duct fibrosis. J Pathol 1999; 189: 609-14.
27. Ishii M, Iwai M, Harada Y et-al. A role of mast cells for hepatic fibrosis in primary sclerosing cholangitis. Hepatol Res 2005; 31: 127-31.
28. Khraishi M. Comparative overview of safety of the biologics in rheumatoid arthritis. J Rheumatol Suppl 2009; 82: 25-32.
29. Tiegs G, Hentschel J, Wendel AA. T cell-dependent experimental liver injury in mice inducible by concanavalin A. J Clin Invest 1992; 90: 196-203.
30. Gantner F, Leist M, Lohse AW, Germann PG, Tiegs G. Concanavalin A-induced T-cell-mediated hepatic injury in mice: the role of tumor necrosis factor. Hepatology 1995; 21: 190-8.
31. Mizuhara H, Uno M, Seki N et-al. Critical involvement of interferon gamma in the pathogenesis of T-cell activation-associated hepatitis and regulatory mechanisms of interleukin-6 for the manifestations of hepatitis. Hepatology 1996; 23: 1608-15.
32. Kimura K, Ando K, Ohnishi H et-al. Immunopathogenesis of hepatic fibrosis in chronic liver injury induced by repeatedly administered concanavalin A. Int Immunol 1999; 11: 1491-500.
33. Louis H, Le Moine A, Quertinmont E et-al. Repeated concanavalin A challenge in mice induces an interleukin 10-producing phenotype and liver fibrosis. Hepatology 2000; 31: 381-90.
34. Wolf AM, Wolf D, Rumpold H et-al. The kinase inhibitor imatinib mesylate inhibits TNF-α production in vitro and prevents TNF-dependent acute hepatic inflammation. Proc Natl Acad Sci USA 2005; 102: 13622-7.